Rankings
▼
Calendar
INDV Q4 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena
INDV
Indivior Pharmaceuticals Inc
$4B
Q4 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$358M
+19.7% YoY
Gross Profit
$294M
82.1% margin
Operating Income
$122M
34.1% margin
Net Income
$103M
28.8% margin
EPS (Diluted)
$0.79
QoQ Revenue Growth
+14.0%
Cash Flow
Operating Cash Flow
-$221M
Free Cash Flow
-$245M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$1.3B
Stockholders' Equity
-$98M
Cash & Equivalents
$195M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$358M
$299M
+19.7%
Gross Profit
$294M
$276M
+6.5%
Operating Income
$122M
$96M
+27.1%
Net Income
$103M
$59M
+74.6%
Revenue Segments
Reportable Segment
$357M
100%
← FY 2025
All Quarters